Bank of America’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Bank of America’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-170	Closed	-$100	–	8652
2024 Q4	$100	Sell	170 -824	-83%	-$571	﹤0.01%	7735
2024 Q3	$784	Buy	994 +784	+373%	+$784	﹤0.01%	7298
2024 Q2	$266	Buy	210 +183	+678%	+$242	﹤0.01%	7496
2024 Q1	$38	Buy	27 +13	+93%	+$21	﹤0.01%	7463
2023 Q4	$22	Buy	+14	New	+$18	﹤0.01%	7639
2023 Q1	–	Sell	-18	Closed	-$26	–	8363
2022 Q4	$26	Buy	+18	New	+$30	﹤0.01%	7932

Bank of America's CYTH Position: Q1 2025 in Review

Bank of America sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 170 shares — an estimated $100 sold.

Bank of America first reported a position in CYTH in Q4 2022 and held it in 6 quarters. The position peaked at $784 in Q3 2024. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

Bank of America reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Bank of America sold 170 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $100.
Bank of America first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2022 and held it in 6 quarters.
Bank of America's Cyclo Therapeutics, Inc. Common Stock position peaked at $784 in Q3 2024.
0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.